Osteoarthritis cartilage regeneration

US6835377B2 · kind B2 · utility

Assignee

• OSIRIS THERAPEUTICS, INC. · US

Inventors

• Victor M. Goldberg · Gates Mills, US
• Arnold I. Caplan · Cleveland Heights, US
• Francis P. Barry · Baltimore, US
• David J. Fink · State College, US
• Daniel Robert Marshak · Weston, US
• James S. Burns · Ann Arbor, US

Key dates

• Filing date: May 13, 1998
• Grant date: Dec 28, 2004
• Expiry date: Nov 23, 2019

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2533/54
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

For repair of cartilage damaged as part of the degenerative effects of osteoarthritis, the inventors have found that the human mesenchymal stem cell approach makes it possible to: (1) regenerate both shallow cartilage chondral defects and full thickness cartilage defects (osteochondral lesions); (2) broaden the suitable clinical population to routinely include middle-aged patients; (3) eliminate the use of autologous tissue grafts (mature cartilage and the periosteal covering) to repair an articular cartilage injury; (4) regenerate other types of injured cartilage such as patellar and spinal disk cartilage; (5) regenerate articular joint cartilage in older patients with osteoarthritis; and (6) form new cartilage and subchondral bone which fully integrate into the adjacent normal tissue.